Program
GSK4382276A
A development code. Also written as “Flu mRNA (Formulation B1)”, “Flu mRNA (Formulation B3)” and “Flu mRNA(Formulation A)”.
In GlaxoSmithKline's pipeline, mRNA vaccine
. Its studies are mostly in Influenza, Human, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 30 open or running | phase 2since Aug 6, 2025 | Jun 28, 2022 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
mRNA Seasonal Flu GSK4382276
, phase 3, as of Sep 30, 2026 (source).
Also a collaborator on its studies: BioNTech.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 28, 2022First study: phase 1 study in Influenza, HumanFirst studyNCT05446740 · 324 enrolled · Belgium, Canada, Spain
- Aug 6, 2025Phase 2 study in Influenza, HumanNCT07121192 · 776 enrolled · United States
- Oct 1, 2025Phase 2 study in Influenza, HumanNCT07204964 · 971 enrolled · United States, Belgium
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“mRNA vaccine”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07204964Influenza, Human · United States, Belgium | 2 | Completed | Aug 24, 2026 | 971 |
| NCT07121192Influenza, Human · United States | 2 | Completed | May 11, 2026 | 776 |
| NCT05446740Influenza, Human · Belgium, Canada, Spain | 1 | Completed | Mar 26, 2024 | 324 |
How it is read
Names in the registry
- “Flu mRNA (Formulation B1)”, 1 entry
- “Flu mRNA (Formulation B3)”, 1 entry
- “Flu mRNA(Formulation A)”, 1 entry
- “Flu mRNA (Formulation A)”, 1 entry
- “Flu mRNA (Formulation B)”, 1 entry
Codes read as this program: GSK4382276A.
Conditions, from the studies’ own filings
- Influenza, Human, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.